Qiagen N.V. provided earnings guidance for year 2024. For the period, Company expects net sales of at least $2.0 billion CER. This reflects full-year total growth of at least 2% CER, with solid mid-single-digit CER sales growth in H2 2024 in the non-COVID portfolio over the year-ago period.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.65 USD | +1.39% | +4.12% | -6.98% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.98% | 9.22B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- QGEN Stock
- News Qiagen N.V.
- Qiagen N.V. Provides Earnings Guidance for Year 2024